Vivos Therapeutics (VVOS) Gross Margin (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Gross Margin data on file, last reported at 59.5% in Q1 2026.

• Gross Margin for Q1 2026 came in at 59.5%, up 947.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 61.8% (up 308.0% YoY), and the FY2025 annual result was 60.44%, up 43.0% from the prior year.
• Gross Margin retreated to 59.5% in Q1 2026 per VVOS's latest filing, from 78.14% in the prior quarter.
• Over five years, Gross Margin peaked at 78.14% in Q4 2025 and troughed at 50.03% in Q1 2025.
• A 5-year average of 60.64% and a median of 60.35% in 2022 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2025: Gross Margin plunged 1873 bps in 2022, then soared 2143 bps in 2025.
• A 5-year view of Gross Margin shows it stood at 60.35% in 2022, then advanced by 7 bps to 64.32% in 2023, then slipped by 12 bps to 56.71% in 2024, then soared by 38 bps to 78.14% in 2025, then fell by 24 bps to 59.5% in 2026.
• Business Quant data shows VVOS's Gross Margin at 59.5% in Q1 2026, 78.14% in Q4 2025, and 58.04% in Q3 2025.